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Adenosine receptor signaling: a key 
to opening the blood–brain door
Margaret S. Bynoe1*, Christophe Viret2, Angela Yan1 and Do‑Geun Kim1
Abstract 
The aim of this review is to outline evidence that adenosine receptor (AR) activation can modulate blood–brain bar‑
rier (BBB) permeability and the implications for disease states and drug delivery. Barriers of the central nervous system 
(CNS) constitute a protective and regulatory interface between the CNS and the rest of the organism. Such barriers 
allow for the maintenance of the homeostasis of the CNS milieu. Among them, the BBB is a highly efficient perme‑
ability barrier that separates the brain micro‑environment from the circulating blood. It is made up of tight junction‑
connected endothelial cells with specialized transporters to selectively control the passage of nutrients required for 
neural homeostasis and function, while preventing the entry of neurotoxic factors. The identification of cellular and 
molecular mechanisms involved in the development and function of CNS barriers is required for a better understand‑
ing of CNS homeostasis in both physiological and pathological settings. It has long been recognized that the endog‑
enous purine nucleoside adenosine is a potent modulator of a large number of neurological functions. More recently, 
experimental studies conducted with human/mouse brain primary endothelial cells as well as with mouse models, 
indicate that adenosine markedly regulates BBB permeability. Extracellular adenosine, which is efficiently generated 
through the catabolism of ATP via the CD39/CD73 ecto‑nucleotidase axis, promotes BBB permeability by signaling 
through A1 and A2A ARs expressed on BBB cells. In line with this hypothesis, induction of AR signaling by selective 
agonists efficiently augments BBB permeability in a transient manner and promotes the entry of macromolecules into 
the CNS. Conversely, antagonism of AR signaling blocks the entry of inflammatory cells and soluble factors into the 
brain. Thus, AR modulation of the BBB appears as a system susceptible to tighten as well as to permeabilize the BBB. 
Collectively, these findings point to AR manipulation as a pertinent avenue of research for novel strategies aiming at 
efficiently delivering therapeutic drugs/cells into the CNS, or at restricting the entry of inflammatory immune cells 
into the brain in some diseases such as multiple sclerosis.
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Background
Neurons of the central nervous system (CNS) are sepa-
rated from the lumen of blood vessels by physical bar-
riers which ensure both protective and homeostatic 
functions [1, 2]. The main barriers are the blood–brain 
barrier (BBB) and its spinal cord counterpart, the blood-
spinal cord barrier. Such barriers are made of tightly 
connected endothelial cells that line the CNS microvas-
culature and form a more highly restrictive barrier than 
endothelial cells of the peripheral circulation. These cells 
are characterized by a markedly restricted pinocytosis 
and trancytosis potential, the expression of dedicated 
transporters that regulate the influx/efflux of nutritive/
toxic compounds, a low expression of leukocyte adhe-
sion molecules and the elaboration of specialized lumi-
nal structures involved in tight and adherens junctions 
that efficiently restrain passive diffusion of blood-borne 
molecules [3–9]. The BBB endothelium is surrounded 
by basement membrane, pericytes and processes from 
neighboring astrocytes that contribute to the so-called 
neurovascular unit (NVU) which regulates barrier func-
tions, homeostasis and stability [10] (Fig.  1). Astrocytes 
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provide nutrients that are important for endothelial cells 
activation/polarization; and they function as a scaffold, 
providing structural support for the vasculature. While 
astrocytic processes enwrap endothelial cells, they also 
interact with microglial cells and neurons [11, 12]. Astro-
cytes regulate BBB tightness by providing soluble factors 
that aid in endothelial cell proliferation and growth or are 
involved in maintenance of BBB integrity [13, 14]. While 
controlling the passage of molecules between the brain 
blood circulation and the brain microenvironment in the 
healthy brain, the BBB may also contribute to the patho-
genesis of several neurological disorders such as neu-
rodegenerative diseases, under conditions of abnormal 
functioning [1]. Therefore, dissecting the mechanisms 
underlying the properties of the BBB is necessary for 
understanding both the physiology of the healthy CNS as 
well as the development of some brain pathologies.
Adenosine is a nucleoside naturally produced by neu-
rons and glial cells. Through a well characterized set of 
receptors called P1 purinergic receptors, adenosine has 
long been known to act as a potent modulator of various 
brain functions through the regulation of multiple neuro-
transmitters, receptors and signaling pathways [15]. Here, 
we review recent in vivo and in vitro studies that point to 
the adenosine-AR axis as an important regulatory path-
way controlling BBB permeability to macromolecules 
and cells, and propose that manipulation of AR signaling 
might represent a new approach to achieve an efficient 
delivery of therapeutic agents into brain parenchyma.
Adenosine and ARs in CNS physiology
Adenosine is a purine nucleoside involved in a myriad 
host functions. It is a potent immune regulator and, in 
addition, is notable for its role in regulating inflamma-
tion, wound healing, angiogenesis and myocardial con-
tractility (Fig. 2). Within the CNS, adenosine is released 
by both neurons and glial cells. It regulates multiple 
physiological functions such as sleep, arousal, neuropro-
tection, learning and memory, cerebral blood circula-
tion as well as pathological phenomena such as epilepsy. 
These effects involve adenosine modulation of neuronal 
excitability, vasodilatation, release of neurotransmitters, 
synaptic plasticity/function and local inflammatory pro-
cesses [15–17] (Fig. 3).
Within cells, adenosine is an intermediate for the syn-
thesis of nucleic acids and adenosine triphosphate (ATP). 
It is generated from 5′-adenosine monophosphate (AMP) 
by 5′-nucleotidase and can be converted back to AMP by 
adenosine kinase. Adenosine can also be derived from 
S-adenosylhomocysteine (SAH) due to the activity of 
SAH hydrolase. Intracellular adenosine is metabolized 
into inosine by adenosine deaminase (ADA) and into 
AMP by adenosine kinase. Inosine formed by deamina-
tion can exit the cell intact or can be degraded to hypox-
anthine, xanthine and ultimately uric acid. A low level of 
cellular adenosine can be quickly released in the extra-
cellular space via equilibrative nucleoside transporters 
(ENTs). This release increases when intracellular adeno-
sine concentration is augmented (ischemia, hypoxia, 
seizures).
Importantly, adenosine can also be directly gener-
ated outside the cell through the breakdown of cell-
released adenosine tri/diphosphate (ATP/ADP) by 
coupled cell surface molecules with catalytically active 
sites (ectonucleotidases) that are abundant in the brain. 
The ecto-nucleoside triphosphate diphosphohydro-
lase 1 (E-NTPDase1) or CD39, converts ATP/ADP into 
AMP and the glycosyl phosphatidylinositol(GPI)-linked 
ecto-5′-nucleotidase (Ecto5′NTase) or CD73, con-
verts AMP to adenosine by promoting the hydrolysis of 
phosphate esterified at carbon 5′ of nucleotides with no 
activity for 2′- and 3′-monophosphates [18, 19]. Human 
CD73 assembles as a dimer of GPI-anchored glyco-
sylated mature molecules. Each monomer contains an 
N-terminal domain that binds divalent metal ions and a 
C-terminal that binds the nucleotide substrate. The ecto-
nucleotidases-mediated generation of adenosine from 
adenine nucleotides is very rapid (about 1 ms). Adenosine 
half-life in the extracellular space is about 10  s. Under 
basal conditions, most extracellular adenosine appears to 
re-enter cells through equilibrative transporters. A small 
fraction can be irreversibly converted into inosine and its 
derivatives (hypoxanthine, xanthine, uric acid) by ADA 
lumen
Brain parenchyma
Astrocytic endfoot
PericyteTight and adherens junctional molecules
Basal lamina
Endothelial cell
Transporters
Fig. 1 Schematic of blood brain barrier (BBB) structure and the 
neurovascular unit (NVU). The brain vasculature is lined with a single 
layer of endothelial cells that is tightly sealed by tight and adherens 
junction molecules. It is further insulated by pericytes and astrocytic 
endfoot processes and in total are referred to as the NVU. Efflux and 
influx transporters expressed on BBB endothelial cells selectively 
allow the entry or exit of molecules into or out of the brain
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and xanthine oxidase (Fig.  2). Such a fraction increases 
under conditions of hypoxia/ischemia [20, 21]. Extracel-
lular adenosine can also be targeted by ectokinases to 
regenerate AMP, ADP and ATP. The concentration of 
extracellular adenosine is maintained at low levels within 
the brain (ranging from 25 to 250 nM) which represent 
the balance between the export/generation of extracel-
lular adenosine and its metabolism. Under pathophysi-
ological circumstances, such as hypoxia or ischemia, 
extracellular adenosine concentrations can increase up to 
100 fold [22, 23]. Because of its rapid metabolism, adeno-
sine acts locally rather than systemically [24].
Extracellular adenosine exerts its action through seven-
transmembrane domain, G-protein coupled receptors 
(GPCRs) that are connected to distinct transduction 
pathways. There are four different subtypes of ARs, A1, 
A2A, A2B and A3 with distinct expression profiles, phar-
macological characteristics and associated signaling path-
ways [25, 26]. A1 and A3 ARs are inhibitory and suppress 
adenylyl-cyclase which produces cyclic-AMP (cAMP) 
while A2A and A2B ARs are stimulatory for adenylyl-
cyclase [27]. In turn, A2B-induced cAMP can upregulate 
Fig. 2 Adenosine is a purine nucleoside produced by many different organs throughout the body. Extracellular adenosine is a primordial molecule 
that is produced by many cell types in the body. These include heart, lung, gut, brain and immune cells. Adenosine produced by these cells can in 
turn act on the producing cells or on adjacent cells to modulate function. Extracellular adenosine is produced from ATP released in the extracel‑
lular environment upon cell damage and is converted to ADP and AMP by CD39. AMP is further converted to adenosine by CD73. Extracellular 
adenosine binds to its receptors expressed on the same cell or adjacent cells to mediate its function. Adenosine is rapidly degraded to inosine by 
adenosine deaminase
Fig. 3 Cells of the central nervous system (CNS) not only produce 
adenosine but are also regulated by adenosine. Cells of the CNS, such 
as astrocytes, microglia, pericytes and neuronal cells can produce 
adenosine or their activity/function is regulated by adenosine. Aden‑
osine regulates the blood brain barrier permeability and is involved in 
neural transmission and glial cell immune function and metabolism
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CD73 [28]. A1 and A2A ARs have high affinity for adeno-
sine (about 70 and 150 nM respectively) whereas A2B and 
A3 have a markedly lower affinity for adenosine (about 
5100 and 6500 nM, respectively) [27]. This suggests that 
A1 and A2A may be the major ARs that are activated by 
physiological levels of extracellular adenosine within 
the CNS. Accordingly, unlike A1 and A2A receptors, A2B 
receptor engagement in the brain is triggered by higher 
adenosine levels such as levels associated with cell stress 
or tissue damage [25]. The expression level of ARs varies 
depending on the type of cells or organs where they are 
expressed [22].
The influence of adenosine in the CNS depends both 
on its local concentration and on the expression level of 
ARs. The A1 receptor is highly expressed in the brain cor-
tex, hippocampus, cerebellum and in spinal cord [25, 29, 
30] and at lower levels at other sites of the brain [31]. In 
multiple sclerosis (MS) patients, the A1 receptor expres-
sion level appears to be decreased in CD45 positive glial 
cells of the brain [32]. The A2A receptor expression is high 
in the olfactory tubercle, dorsal and ventral striatum and 
throughout the choroid plexus which forms the blood-
cerebrospinal fluid (CSF) barrier [33–36] and more 
moderate in the meninges, cortex and hippocampus 
[29, 33, 36]. The steady state expression of A2A receptor 
permits for example the proper regulation of extracellu-
lar glutamate titer by adenosine, through modulation of 
glutamate release and control of glutamate transporter-
1-mediated glutamate uptake [37–39]. A2A receptors 
interact negatively with D2 dopamine receptors [40]. 
A2A receptor expression in glial cells such as astrocytes 
is substantially upregulated by stress factors including 
pressure, pro-inflammatory factors (interleukin (IL)-1β, 
tumor necrosis factor (TNF)-α) or hypoxia. In contrast to 
A1 and A2A, A2B and A3 receptors are expressed at rela-
tively low levels within brain [31].
Expression of the CD73 ecto‑enzyme on CNS 
barrier cells
Some studies have pointed to CD73 as a regulator of tis-
sue barrier function [41]. Within the CNS, ATP can be 
released from neurons or other cells such as astrocytes. 
As mentioned above, CD39 catalyses the conversion of 
proinflammatory ATP/ADP into AMP and CD73 sub-
sequently converts AMP into adenosine [42]. Thus, the 
proper functioning of CD39/CD73 ectonucleotidases 
concomitantly ensures the production of extracellular 
adenosine and the extinction of purinergic P2 receptor-
dependent, ATP-induced signaling due to reduction of 
the ATP/ADP pool. Both of these effects contribute to 
the anti-inflammatory potential of the CD39/CD73 axis. 
Along with colon and kidney, the brain has particularly 
high levels of CD73 enzyme activity [41]. Similar to the 
A2A receptor, CD73 shows its strongest expression level 
in the CNS within the choroid plexus epithelium and is 
also detected on glial cells of the submeningeal areas of 
the spinal cord [22, 27, 43]. CD73 can be expressed on 
many types of endothelial cells [44]. Its expression on 
BBB endothelial cells remains low under steady state con-
ditions relative to peripheral endothelial cells (Fig. 4a). It 
is present on mouse (Bend.3) and human (hCMEC/D3) 
brain endothelial cell lines in vitro [27, 45]. Unlike human 
brain endothelial cells [46, 47], CD73 expression on pri-
mary mouse brain endothelial cells was very low and not 
detected in  vivo [43] (Fig.  4a). However, CD73 expres-
sion can be detected in primary human brain endothelial 
a b
Anti-CD73
Isotype
Unstained
Fig. 4 CD73 expression on primary brain endothelial cells (EC). a Histogram depicting CD73 expression on primary brain endothelial cells isolated 
from naïve, WT, C57BL/6 mice after staining with a monoclonal antibody to CD73 and analyzed by FACS. b Expression of CD73 (green) on cultured 
primary human brain endothelial cells visualized by immunofluorescent microscopy. Cells were counterstained with F‑actin (red). Scale bar is 50 μm
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cells (Fig.  4b) [45, 48]. CD73 expression is sensitive to 
cyclic AMP (cAMP) and hypoxia-inducible factor (HIF)1 
through its promoter [49]. Interferon (IFN)-β increases 
CD73 expression and adenosine concentration at the 
level of the CNS microvasculature, BBB and astrocytes 
[46, 47] and through enhanced adenosine production, 
may contribute to the anti-inflammatory effect of IFN-β 
in MS treatment.
AR signaling in the NVU
Functional A1, A2A, A2B and A3 receptors are all 
expressed at moderate levels in glial cells under physi-
ological context [50] and this level is upregulated under 
inflammatory conditions or brain injury. All P1 puriner-
gic receptors appear to be present on cultured oligoden-
drocytes [51], on microglial cells [42] and are functional 
on astrocytes [52–56] (Fig. 3). In astrocytes, ARs engage-
ment is not only important for glutamate uptake reg-
ulation (A2A receptor) but also to maintain cellular 
integrity (A1 receptor) [53, 57, 58], protect from hypoxia-
related cell death (A3 receptor) [57] and regulate CCL2 
chemokine production (A3 receptor) [59]. In microglial 
cells, A2A receptor engagement inhibits process exten-
sion and migration while A1 and A3 receptors engage-
ment have the opposite effect [42]. A1 and A2A receptor 
transcripts are detectable in Z310 epithelial cells derived 
from mouse choroid plexus [43]. As to CNS endothelial 
cells, A1, A2A and A2B receptor transcripts and proteins 
were expressed in hCMEC/D3 human brain endothelial 
cells [45]. Also, A1 and A2A ARs are expressed in primary 
human brain endothelial cells (Fig. 5a). In Bend.3 mouse 
brain endothelial cells, transcripts and proteins for A1 
and A2A receptors were detected [27]. Finally, both A1 
and A2A receptor proteins were found expressed in pri-
mary mouse brain endothelial cells and transcripts and 
proteins for both A1 and A2A receptors were present in 
brain endothelial cells in mice [27] (Fig. 5b).
AR signaling and CNS barrier permeability
The recent notion that adenosine could play a substantial 
regulatory role in CNS barrier permeability stems from 
the observation that extracellularly generated adeno-
sine positively regulates the entry of lymphocytes into 
the brain and spinal cord during disease development in 
the experimental autoimmune encephalomyelitis (EAE) 
model [43] and the observation that irradiated A2A AR 
deficient mice reconstituted with wild-type bone marrow 
cells developed only very mild signs of EAE with virtu-
ally no CD4+ T cell infiltration in spinal cord [43]. In line 
with an important role for AR signaling in regulating the 
permeability of the BBB is the observation that inhibi-
tion of ARs by caffeine (a broad-spectrum AR antago-
nist) prevents the alteration of BBB function induced by 
cholesterol or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyri-
dine (MPTP) in animal models of neurodegenerative dis-
eases [60, 61].
Recent observations support the notion that engage-
ment of ARs on brain endothelial cells modulates BBB 
permeability in  vivo. Experimental recruitment of ARs 
either by the broad spectrum agonist NECA or the 
engagement of both A1 and A2A receptors by selective 
agonists (CCPA and CGS21680) cumulatively and tran-
siently augmented BBB permeability facilitating the 
entry of intravenously infused macromolecules (includ-
ing immunoglobulins such as the anti-β-amyloid 6E10 
antibody) into the CNS [27]. Accordingly, the analysis of 
engineered mice lacking these receptors reveals a limited 
entry of macromolecules into the brain upon exposure 
to AR agonists. CNS entry of intravenously delivered 
macromolecules was also induced by the FDA-approved, 
A2A AR agonist Lexiscan: 10  kDa dextran was detect-
able within the CNS of mice as soon as 5 min after drug 
A1 AR A2A AR
a
b
Fig. 5 Expression of adenosine receptors (ARs) and adenosine‑
generating enzymes on brain endothelial cells. a A1 and A2A ARs 
expression green on primary human brain endothelial cells by 
immunofluorescence assay (IFA). Cells were counterstained with 
F‑actin (red). b Relative mRNA expression level of ARs, CD39 and CD73 
by quantitative PCR (q‑PCR) in mouse primary brain endothelial cells. 
Scale bar is 50 μm
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injection. The maximum increase in BBB permeability 
was observed at about 30 min after injection both in mice 
and rats. The limited half-life of Lexiscan (about 3 min) 
is likely to account for the lower duration of BBB perme-
ability relative to that induced by NECA (half-life: 5 h).
Upon exposure to NECA or Lexiscan, monolayers of 
Bend3 mouse brain endothelial cells (CD73+, A1 AR+, 
A2A AR+) lowered their transendothelial cell electrical 
resistance, a phenomenon known to be associated with 
increased paracellular space and augmented permeability 
[62, 63]. AR activation by agonists was indeed associated 
with augmented actinomyosin stress fiber formation indi-
cating that ARs signaling initiates changes in cytoskeletal 
organization and cell shape. These processes are reversed 
as the half-life of the AR agonist decreases. At the level of 
tight junctions, signaling induced by A1 and A2A recep-
tor agonists altered the expression level of tight junction 
proteins such as claudin-5 and ZO-1, and particularly 
of occludin in cultured brain endothelial cells [27]. The 
exact signaling circuits connecting AR engagement and 
cytoskeletal remodeling remain to be dissected. In agree-
ment with these findings and with the observation that 
human brain endothelial cells do respond to adenosine 
in  vitro, agonist-induced A2A receptor signaling tran-
siently permeabilized a primary human brain endothelial 
cell monolayer to the passage of both drugs and Jurkat 
human T cells in vitro [48]. Interestingly, transendothe-
lial migration of Jurkat cells was primarily of the paracel-
lular type. The permeabilization process involved RhoA 
signaling-dependent morphological changes in actin-
cytoskeletal organization, a reduced phosphorylation of 
factors involved in focal adhesion (namely Ezrin-Radixin-
Moesin (ERM) and focal adhesion kinase (FAK)) as well 
as a marked downregulation of both claudin-5 and vas-
cular endothelial (VE)-cadherin [48], two factors instru-
mental for the integrity of endothelial barriers. Hence, 
by regulating the expression level of factors crucially 
involved in tight junction integrity/function, signaling 
induced through receptors for adenosine acts as a potent, 
endogenous modulator of BBB permeability in mouse 
models as well as in human cellular models in vitro.
Some G proteins such as Gα subunits can influence the 
activity of small GTPases RhoA and Rac1 that are known 
modulators of cytoskeletal organization. RhoA and Rac1 
are responsive to adenosine signaling and promote actin 
cytoskeleton remodeling [62, 64–66]. The precise molec-
ular events linking A1/A2A AR engagement to changes in 
the expression pattern of factors involved in tight junc-
tion functioning remains however to be analyzed in 
detail. In particular, whether both canonical (G protein-
dependent) and non-canonical (e.g. G protein-independ-
ent, β-arrestin-related) signaling pathways contribute to 
such regulation is an open question. Another interesting 
issue relates to the capacity of A1 and A2A receptors to 
form heterodimers [67] and the possible impact of such 
oligomeric receptors on the regulation of CNS barrier by 
ARs agonists.
CD73 and AR signalling in immune cell entry 
into the CNS
Besides its capacity to regulate the local inflammatory 
context through consumption of ATP and generation of 
adenosine, the expression of CD39/CD73 by endothe-
lial cells can regulate homeostasis by preventing high 
local concentrations of ATP that promote thrombosis 
and generating adenosine which instead, contributes to 
an antithrombotic microenvironment [44]. The CD39/
CD73 axis also regulates leukocyte migration induced 
by chemokines [68, 69] and immune cell adhesion to 
endothelial cells. Such adhesion is favored by high ATP 
concentrations and limited by adenosine, with mutant 
mice lacking CD39 or CD73 having augmented level of 
leukocyte adhesion to endothelial cells [70, 71]. Thus, 
adenosine contributes to restraining leukocyte recruit-
ment and platelet aggregation and might be important to 
control vascular inflammation.
We have observed that CD73-generated adenosine pro-
motes the entry of inflammatory lymphocytes into the 
CNS during EAE development [43]. Genetically manipu-
lated mice unable to generate extracellular adenosine due 
to deficiency in the ectonucleotidase CD73 (CD73−/−) 
are resistant to lymphocyte entry into the CNS and EAE 
development relative to wild type animals and such a phe-
notype could be recapitulated in regular mice by using 
either the broad spectrum AR antagonist, caffeine or 
the SCH58261 that selectively antagonizes the signaling 
induced by adenosine-bound A2A receptor [43, 72–74]. 
This effect was remarkable since auto-reactive lympho-
cytes from CD73−/− mice indeed harbor an enhanced 
inflammatory potential. In addition, the expression of 
CD73 (and presumably its enzymatic activity) on either 
T cells or CNS cells was sufficient to support lympho-
cyte entry into the CNS since CD4 T cells from wild type 
donors (i.e. CD73+) could mediate a milder yet substan-
tial level of EAE pathogenesis in CD73−/− recipient mice 
[43].
Since CD73 and the A1/A2A receptors are expressed at 
the level of the choroid plexus, locally produced extracel-
lular adenosine is likely to act in an autocrine manner. 
Given that A1 and A2A receptor recruitment are function-
ally opposed to each other and harbor some differences in 
their affinity for adenosine [26], the regional extracellular 
concentration of adenosine may strongly influence the 
response of neighboring cells expressing both receptors. 
A1 receptor signaling may be involved at low adenosine 
concentrations while A2A receptor signaling is likely to 
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become prominent at elevated adenosine concentrations. 
Thus, CD73 enzymatic activity at the choroid plexus and 
the regional adenosine levels are likely to influence local 
inflammatory events. Interestingly, the choroid plexus is 
suspected to represent a primary entry site for immune 
cells during neuroinflammation [3–5] and for steady 
state immunosurveillance [6, 75]. By combining the 
gene expression pattern of chemokines and chemokine 
receptors relevant to EAE in CD73 null mutant versus 
control mice developing EAE and the effect of the broad 
spectrum AR agonist NECA on the expression profile 
of these molecules in unmanipulated animals, it was 
possible to identify CX3CL1/fractalkine, a chemokine/
adhesion molecule [76], as the major factor induced by 
extracellular adenosine in the brain of mice developing 
EAE [77]. The cleavage of the cell surface-expressed form 
of CX3CL1 by ADAM-10 and −17 factors generates a 
local CX3CL1 gradient [78]. The selective A2A AR agonist 
CGS21680 caused an increase in CX3CL1 level in the 
brain of treated mice. Conversely, the A2A AR antagonist 
SCH58261 protected mice from CNS lymphocyte infil-
tration and EAE induction recapitulating the phenotype 
of CD73 null mutant mice. Thus, the augmented CX3CL1 
expression level seen in the brain of EAE developing mice 
can be regulated by A2A AR signaling. During EAE, the 
greatest increase in CX3CL1 occurred at the choroid 
plexus and returned to normal when mice recovered 
from disease. As choroid plexus cells express both CD73 
and A2A AR, they have the intrinsic capacity to gener-
ate and respond to extracellular adenosine. In vitro, A2A 
AR engagement on the choroid plexus epithelial cell line 
CPLacZ-2 by CGS21680 induced CX3CL1 expression 
and promoted lymphocyte transmigration suggesting 
that CX3CL1 induction by extracellular adenosine con-
tributes to lymphocyte migration into the brain paren-
chyma during EAE. In agreement with an important role 
for CX3CL1 in EAE pathogenesis is the fact that CX3CL1 
blockade by neutralizing antibodies prevented lympho-
cyte entry into the CNS and EAE development [77]. This 
notion is in line with the elevated serum level of CX3CL1 
which can be observed during CNS inflammation includ-
ing MS patient brain lesions [79–81]. Importantly, there 
was a positive correlation between CX3CL1 expression 
levels and the relative frequency of lymphocytes pre-
sent in the CSF of inflamed brains [80, 82]. Moreover, 
relative to BBB endothelial cells, choroid plexus epithelial 
cells constitutively express high levels of CD73. Block-
ade of CD73 or A2A AR inhibits inflammatory cells entry 
into the CNS [43, 77]. Thus, at the level of the choroid 
plexus, induction of A2A receptor signaling by elevated 
local adenosine concentrations is likely to contribute to 
immune cell entry into the brain parenchyma.
Among immune cells, the CX3CL1 receptor (CX3CR1) 
was detected on a sizable fraction of CD4 T cells, CD8 
T cells, macrophages and NK cells in mice [33]. CNS 
CX3CL1 might also modulate neuroinflammation by 
recruiting a subset of CNS resident NK cells able to 
attenuate the aggressiveness of autoreactive CD4 T cells 
of the Th17 effector type [83, 84]. Interestingly, while the 
frequency of inflammatory immune cells is significantly 
decreased in the CNS of A2A AR−/−, CD73−/− or mice 
treated with A2A AR antagonist, the numbers/frequency 
of CD4+CD25+ T regulatory cells in these mice were 
similar to WT. This suggests that CD73/A2A AR signaling 
may preferentially regulate inflammatory immune cells 
entry into the CNS but confers less stringency on these 
suppressor T cells.
Perspectives for improved delivery of therapeutic 
factors within the CNS
Although the BBB serves a protective role, it can con-
stitute a complication for treatment in CNS diseases 
by hindering the entry of therapeutic compounds into 
the brain [85]. Researchers have focused on uncovering 
ways to manipulate the BBB to promote access to the 
CNS [86]. Determining how to safely and effectively do 
this could impact the treatment of various neurological 
diseases, ranging from neurodegenerative disorders to 
brain tumors. This implies simultaneous treatments with 
agents susceptible to increase permeation of CNS barri-
ers. Current approaches involve barrier disruption which 
is induced by drugs such as mannitol or Cereport/RMP-
7. Hypertonic mannitol, is active through shrinking of 
endothelial cells [87, 88] but can cause epileptic seizures 
and does not allow for repeated use [89, 90]. The brady-
kinin analog (Cereport/RMP-7) has shown some poten-
tial in transiently increasing normal BBB permeability 
[91] but did not give satisfactory results in clinical trial 
[92] despite some efficacy in treating rodent models of 
CNS pathologies [93–96].
The barrier permeability can also be circumvented, for 
instance by direct injection of drugs into ventricles [87, 
97]. More recent approaches involve the delivery of drugs 
during compression waves induced by high-intensity 
focused ultrasounds [98]. Both these approaches are inva-
sive and may lead to permanent brain damage. Another 
strategy involves chemical modifications of compounds 
in order to confer upon them some capacity to cross 
CNS barriers. For example, increasing the lipophilic-
ity of drugs can enhance their capacity to cross the BBB 
although it often requires an increase in their size which 
limits the cell penetration capacity [99]. Alternatively, 
therapeutic compounds can be linked to factors that 
trigger receptor-mediated endocytosis. Coupling a com-
pound to an antibody directed to the transferrin receptor 
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can promote delivery of proteins to the brain in rats [100, 
101]. However, the endocytic activity of endothelial cells 
is rather limited at the BBB and the expression level of 
the relevant receptor needs to be sufficient.
For adenosine to exert biological effect, CD73 and ARs 
must be present on the same cell or on adjacent cells, 
because adenosine acts locally due to its short half-life. 
CD73, A1 and A2A ARs are indeed expressed on BBB 
endothelial cells in mice and humans. While CD73 is 
highly and constitutively expressed on choroid plexus 
epithelial cells that form the blood to CSF barrier, its 
expression on brain endothelial barrier cells is low under 
steady state conditions, but increases in neuroinflam-
matory diseases or under conditions where adenosine 
is produced in response to cell stress/inflammation or 
tissue damage. In mice, pharmacological activation or 
inhibition of the A2A AR expressed on BBB cells opens 
and tightens the BBB, respectively, to entry of macro-
molecules or cells. The observation that adenosine can 
modulate BBB permeability upon A2A receptor activa-
tion suggest that this pathway might represent a valuable 
strategy for modulating BBB permeability and promote 
drug delivery within the CNS [27, 48]. Factors such as 
the FDA-approved, A2A AR agonist Lexiscan, or a broad-
spectrum agonist, NECA, increased BBB permeabil-
ity and supported macromolecule delivery to the CNS 
in experimental setting [27]. Such exogenous agonists 
might represent a new avenue of research for therapeu-
tic macromolecule delivery to the human CNS. Of note 
is the fact that the window of the induced permeability 
correlated with the half-life of the agonist. Thus, BBB 
permeation induced by NECA treatment (half-life, 4  h) 
lasted significantly longer than that induced by Lexiscan 
treatment (half-life, 2.5  min) [27]. Interestingly, despite 
its short half-life, extracellular adenosine permeabilized 
the BBB to entry of 10 kDa dextran (Fig. 6). Approaches 
based on the use of such an agonist might be useful for 
the delivery of therapeutic antibodies to the CNS since 
invasive delivery is a commonly used method [102] and is 
not patient-friendly.
Further studies are needed to better understand the 
mechanisms involved in BBB permeability modulation 
by A1/A2A receptors-triggered signaling as well as the 
parameters susceptible to optimize the timing of such 
a modulation (Fig.  7). In particular, in  vitro cell based 
model of BBB where cerebral endothelial cells are co-
cultured with other components of the NVU such as 
pericytes or astrocytes (co-cultures and triple co-cul-
tures systems) [103] should be considered for evalua-
tion. Another important issue relates to the question of 
the identification of the CNS areas where the microvas-
culature is significantly permeabilized by A1/A2A recep-
tor-induced signaling and more generally whether or 
not, there exists a restricted or a global permeabilization 
within the CNS. An alternative strategy to be explored 
is the experimental manipulation of the regional level of 
endogenous adenosine or of the responsiveness/expres-
sion level of A1/A2A receptors. Such knowledge will 
be instrumental in designing novel approaches for the 
improved delivery of drugs, therapeutic monoclonal anti-
bodies and possibly, stem cells, within the CNS.
Concluding remarks
Inhibiting AR signaling on BBB cells restricts the entry 
of macromolecules and inflammatory immune cells into 
the CNS with limited impact on anti-inflammatory, T 
regulatory cells. Conversely, activation of ARs on BBB 
cells promotes entry of small molecules and macromole-
cules in the CNS in a time-dependent manner. The dura-
tion of BBB permeabilization depends on the half-life of 
the AR activating agent or agonist, suggesting that AR 
modulation of the BBB is a tunable system. We conclude 
that: (1) The adenosine-based control of the BBB is an 
endogenous mechanism able to regulate cells and mol-
ecules entry into the CNS in basal conditions and during 
response to CNS stress or injury. (2) AR-induced opening 
of the BBB is time-dependent and reversible. (3) A tight 
regulation of CD73 expression on BBB cells is crucial to 
restrict and regulate adenosine bioavailability and pre-
vent promiscuous BBB permeability.
Consequently, the control of BBB permeability via 
modulation of AR signaling is pertinent for research on 
the delivery of therapeutics to the CNS: (1) AR signal-
ing is an endogenous mechanism for BBB control. (2) 
It has the potential for precise time-dependent control 
of BBB permeability. (3) Change in BBB permeability 
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Fig. 6 Adenosine increases the permeability of the blood brain bar‑
rier to 10 kDa FITC dextran. Concomitant administration of Adenosine 
and 10 kDa FITC‑Dextran in C57BL/6 mice with exogenous adenosine 
induces significantly higher accumulation of FITC‑Dextran into the 
brain than PBS control treatment group (n = 2, asterisk indicates 
p < 0.01)
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is reversible. (4) ARs are accessible directly on BBB 
endothelial cells. (5) Over 50 commercial reagents target-
ing ARs are available, with some approved by the FDA for 
clinical use. (6) In vivo and in  vitro model systems can 
help to gain molecular mechanistic understanding of how 
adenosine naturally regulates changes in BBB perme-
ability. Therapies aimed at treating neuro-inflammatory 
diseases such as MS, where inflammatory cells penetra-
tion of the CNS causes irreparable damage to CNS tissue, 
would ideally include one that could inhibit the entry of 
inflammatory immune cells into the CNS parenchyma. 
Many other diseases associated with CNS inflammation 
such as meningitis, encephalitis, and cerebritis could all 
benefit from inhibiting immune cell entry into the CNS. 
The challenge is determining how to safely and effectively 
do this. We hypothesize that manipulating the adeno-
sine-ARs axis on CNS barrier cells may represent an effi-
cient way to modulate the entry of immune cells into the 
CNS and to limit CNS inflammation and pathology.
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Fig. 7 A model: Adenosine modulation of blood brain barrier (BBB) permeability. Endothelial cells lining the brain vasculature express adenosine 
receptors (ARs) and CD39 and CD73. In the presence of cell stress/inflammation or tissue damage (a), ATP is released and is rapidly converted to 
ADP and AMP by CD39 (b) and AMP is converted to adenosine by CD73. c Adenosine binds to its receptor/s (A1 or A2A) on BBB endothelial cells (d), 
the activation of which induces reorganization of actin cytoskeleton in BBB endothelial cells, resulting in tight and adherens junction disassembly 
(e), increasing paracellular permeability
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